To review the literature leading to the Food and Drug Administration (FDA) approval of the first medication, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH), including the pharmacology, pharmacokinetics, clinical studies, dosing, and adverse effects. Relevant data will be used to discuss how resmetirom impacts clinical practice.
Data sources:
A literature search was conducted using MEDLINE from database inception to May 12, 2024. Keywords included non-alcoholic steatohepatitis, nonalcoholic fatty liver disease, and resmetirom. Study selection, data extraction and all English-language studies involving the use of resmetirom for nonalcoholic fatty liver disease (NAFLD)/NASH were included.
Data synthesis:
Resmetirom, a thyroid hormone receptor agonist, is administered at daily doses of either 80 mg or 100 mg. The drug was shown to provide NASH resolution as assessed by the NAFLD activity score, 80 mg-24.2%, 100 mg-25.9% compared to 14.2% with the placebo group (P < 0.001). Resmetirom, improved liver fibrosis, 80 mg-25.9%, 100 mg-29.9% compared to 9.7% with the placebo group (P < 0.001). Resmetirom’s ability to improve fibrosis in patients with F2-F3 fibrosis offers valuable benefit for patients at risk of progressing to cirrhosis.
Relevance to patient care and clinical practice:
Resmetirom expands the medication options available to treat patients with NASH which can be given alongside other medications to optimize metabolic factors such as glucagon-like peptide-1 and hydroxymethylglutaryl-coenzyme A reductase inhibitors. Resmetirom was well tolerated in studies.
Conclusion:
Resmetirom serves as an attractive option in patients diagnosed with NASH with evidence of advanced fibrosis (F2-F3) in combination with exercise, diet, and other multimodal therapies targeting metabolic risk factors.
KanwalFNeuschwander-TetriBALoombaRRinellaME.Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212–1219. doi:10.1097/HEP.0000000000000670
2.
RinellaMENeuschwander-TetriBASiddiquiMS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/hep.0000000000000323
3.
YounossiZMKoenigABAbdelatifDFazelYHenryLWymerM.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
HarrisonSABashirMRGuyCD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2019;394(10213):2012-2024. doi:10.1016/S0140-6736(19)32517-6
6.
HarrisonSATaubRNeffGW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919-2928. doi:10.1038/s41591-023-02603-1
7.
HarrisonSABedossaPGuyCD, et al. A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000
8.
HarveyBE.NASH: regulatory considerations for clinical drug development and U.S. FDA approval. Acta Pharmacol Sin. 2022;43(5):1210-1214. doi:10.1038/s41401-021-00832-z
9.
RinellaMELazarusJVRatziuV, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol Baltim Md. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520
10.
RazaSRajakSUpadhyayATewariAAnthony SinhaR.Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci Landmark Ed. 2021;26(2):206-237. doi:10.2741/4892
11.
WongRJAguilarMCheungR, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-555. doi:10.1053/j.gastro.2014.11.03.9
12.
ChalasaniNYounossiZLavineJE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328-357. doi:10.1002/hep.29367
MarginiCDufourJF.The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 2016;36(3):317-324. doi:10.1111/liv.13031
15.
LudwigJViggianoTRMcGillDBOhBJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-438
16.
ArnoldJIdalsoagaFDíaz PigaL, et al. Emerging drug therapies for metabolic dysfunction-associated steatotic liver disease: a glimpse into the horizon. Curr Hepatol Rep. 2024;23:1-16. doi:10.1007/s11901-023-00629
17.
LonardoA.Resmetirom: finally, the Light at the End of the NASH Tunnel?Livers. 2024;4(1):138-141. doi:10.3390/livers4010010
18.
AlkhouriN.Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196). Expert Opin Investig Drugs. 2020;29(2):99-101. doi:10.1080/13543784.2020.1708899
19.
KarimGBansalMB.Resmetirom: an orally administered, smallmolecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis. touchREV Endocrinol. 2023;19(1):60-70. doi:10.17925/EE.2023.19.1.60
20.
GeorgeESReddyANicollAJ, et al. Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: the MEDINA randomised controlled trial. Liver Int. 2022;42(6):1308-1322. doi:10.1111/liv.15264
21.
YurtdaşGAkbulutGBaranMYılmazC.The effects of Mediterranean diet on hepatic steatosis, oxidative stress, and inflammation in adolescents with non-alcoholic fatty liver disease: a randomized controlled trial. Pediatr Obes. 2022;17(4):e12872. doi:10.1111/ijpo.12872
22.
KawaguchiTCharltonMKawaguchiA, et al. Effects of Mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials. Semin Liver Dis. 2021;41(3):225-234. doi:10.1055/s-0041-1723751
23.
HaighLKirkCEl GendyK, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913-1931. doi:10.1016/j.clnu.2022.06.037
24.
ChenYPLuFBHuYBXuLMZhengMHHuED. A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38(6):2552-2557. doi:10.1016/j.clnu.2018.11.030
25.
SaabSMallamDCoxGAIITongMJ.Impact of coffee on liver diseases: a systematic review. Liver Int. 2014;34(4):495-504. doi:10.1111/liv.12304
26.
SemmlerGDatzCReibergerTTraunerM.Diet and exercise in NAFLD/NASH: beyond the obvious. Liver Int. 2021;41(10):2249-2268. doi:10.1111/liv.15024
27.
PatelNSDoychevaIPetersonMR, et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015;13(3):561-568.e1. doi:10.1016/j.cgh.2014.08.039
28.
ArmstrongMJGauntPAithalGP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet. 2016;387(10019):679-690. doi:10.1016/S0140-6736(15)00803-X
29.
Eli Lilly and Company. A randomized, double-blind, placebo-controlled phase 2 study comparing the efficacy and safety of tirzepatide versus placebo in patients with nonalcoholic steatohepatitis (NASH). ClinicalTrials.gov. Published 2023. Accessed December 31, 2023. https://clinicaltrials.gov/study/NCT04166773
30.
NewsomePNBuchholtzKCusiK, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395
CusiKIsaacsSBarbD, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
34.
BlondeLUmpierrezGEReddySS, et al. American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocr Pract. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002
35.
StineJGMunaganuruNBarnardA, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(11):2274-2283. doi:10.1016/j.cgh.2020.08.061
36.
JungJLoombaRRImajoK, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut. 2021;70(10):1946-1953. doi:10.1136/gutjnl-2020-322976
37.
Standards of care in diabetes2024. Amercan Diabetes Assoc. 2023;47:(S1-S4). doi:10.2337/dc24-SINT
38.
HarrisonSABashirMMoussaSE, et al. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021;5(4):573-588. doi:10.1002/hep4.1657
39.
YounossiZMStepanovaMTaubRABarboneJMHarrisonSA.Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol. 2022;20(6):1354-1361. doi:10.1016/j.cgh.2021.07.039
40.
HarrisonSARatziuVAnsteeQM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024;59(1):51-63. doi:10.1111/apt.17734
41.
Madrigal Pharmaceuticals Inc. A randomized double-blind placebo-controlled phase 3 study to evaluate the effect of resmetirom on liver-related outcomes in patients with well-compensated (Child-Pugh A) non-alcoholic steatohepatitis (NASH) cirrhosis (MAESTRO-NASH-OUTCOMES). ClinicalTrials.gov. Published 2023. Accessed December 31, 2023. https://clinicaltrials.gov/study/NCT05500222
42.
CusiK.Selective agonists of thyroid hormone receptor beta for the treatment of NASH. N Engl J Med. 2024;390(6):559-561. doi:10.1056/NEJMe2314365
JavanbakhtMFishmanJMoloneyERydqvistPAnsaripourA.Early cost-effectiveness and price threshold analyses of resmetirom: an investigational treatment for management of nonalcoholic steatohepatitis. Pharmacoeconomics Open. 2022;7(1):93-110. doi:10.1007/s41669-022-00370-2
45.
MannJFEFonsecaVMosenzonO, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation. 2018;138(25):2908-2918. doi:10.1161/CIRCULATIONAHA.118.036418
46.
SorliCHarashimaSITsoukasGM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260. doi:10.1016/S2213-8587(17)30013-X
47.
LincoffAMBrown-FrandsenKColhounHM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
48.
Syed-AbdulMM.Expanding pharmacists’ role in the management of non-alcoholic fatty liver disease. Pharmacy. 2023;11(5):151. doi:10.3390/pharmacy11050151
